Physician profile
Jina Kim
NPI 1114155702
$21,056.30
in general payments reported to CMS, 2019-2025
61 companies · $2,122 in 2025
The $2,122 reported for 2025 was more than what 96% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $3,704 · 2020: $2,986 · 2021: $3,197 · 2022: $3,017 · 2023: $2,951 · 2024: $3,079 · 2025: $2,122.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $8,058 · Education: $94.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $8,058.38 |
| Education | $94.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $2,719.45 | 2019-2025 | Evenity, Prolia, Repatha |
| Abbvie INC. | $2,708.58 | 2019-2025 | |
| Amarin Pharma, INC. | $1,698.52 | 2019-2023 | |
| Pfizer INC. | $1,381.25 | 2019-2025 | |
| Sanofi-Aventis U.S. LLC | $1,019.54 | 2019-2023 | |
| Gilead Sciences, INC. | $1,003.29 | 2019-2025 | Vemlidy |
| Radius Health, INC. | $995.92 | 2019-2025 | Tymlos |
| Astrazeneca Pharmaceuticals LP | $962.04 | 2019-2025 | Farxiga, Airsupra, Breztri |
| Novo Nordisk INC | $925.30 | 2019-2025 | Ozempic, Rybelsus |
| Lilly USA, LLC | $878.43 | 2019-2025 | Zepbound, Jardiance, Mounjaro |
| Bayer Healthcare Pharmaceuticals INC. | $554.12 | 2021-2025 | |
| Astellas Pharma US INC | $531.04 | 2019-2025 | Veozah, Myrbetriq |
| Biohaven Pharmaceutical Holding Company LTD. | $434.08 | 2022 | |
| Glaxosmithkline, LLC. | $389.59 | 2019-2025 | Shingrix, Arexvy, Bexsero |
| Merck Sharp & Dohme LLC | $370.24 | 2019-2025 | Capvaxive, Gardasil 9 |
Show all 61 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $343.97 | 2019-2023 | Xarelto |
| Boehringer Ingelheim Pharmaceuticals, INC. | $329.41 | 2019-2024 | Jardiance |
| Kowa Pharmaceuticals America, INC. | $297.23 | 2019-2025 | Livalo, Seglentis, Zoryve |
| Ardelyx, INC. | $296.97 | 2023-2025 | Ibsrela |
| Nestle Healthcare Nutrition INC. | $296.27 | 2020-2023 | |
| Scilex Pharmaceuticals INC. | $252.09 | 2020-2024 | Ztlido |
| Esperion Therapeutics, INC. | $242.54 | 2021-2025 | Nexletol |
| Sumitomo Pharma America, INC. | $225.25 | 2024-2025 | Gemtesa, Myfembree |
| Novartis Pharmaceuticals Corporation | $185.52 | 2019-2021 | |
| Arbor Pharmaceuticals, INC. | $157.52 | 2019-2021 | |
| Dexcom, INC. | $144.87 | 2022-2025 | Dexcom G6 Transmitter |
| Exact Sciences Corporation | $132.18 | 2023-2025 | Cologuard Collection Kit |
| Aimmune Therapeutics, INC. | $132.15 | 2024-2025 | Zenpep |
| Vivus LLC | $111.23 | 2021-2022 | |
| Alexion Pharmaceuticals, INC. | $105.60 | 2020-2024 | Strensiq |
| Allergan, INC. | $100.40 | 2019-2020 | |
| Vbi Vaccine (Delaware) INC. | $98.22 | 2022-2023 | Prehevbrio |
| Corcept Therapeutics | $97.59 | 2019-2025 | Korlym |
| Teva Pharmaceuticals USA, INC. | $91.64 | 2019-2020 | |
| Ibsa Pharma INC. | $85.12 | 2022-2024 | Tirosint, Licart, Licart |
| Sunovion Pharmaceuticals INC. | $56.30 | 2022 | |
| Corium, LLC | $56.15 | 2023 | Adlarity |
| Alk-Abello, INC | $54.29 | 2024 | Grastek, Odactra, Ragwitek |
| Paratek Pharmaceuticals, INC. | $44.46 | 2020 | |
| Lundbeck LLC | $44.28 | 2022-2025 | Rexulti |
| Xeris Pharmaceuticals, INC. | $38.45 | 2023 | Gvoke Hypopen |
| Almatica Pharma LLC | $38.10 | 2025 | Teriparatide, Loreev Xr |
| Sanofi Pasteur INC. | $35.62 | 2019-2022 | |
| Phathom Pharmaceuticals, INC. | $34.12 | 2024-2025 | Voquezna |
| Azurity Pharmaceuticals, INC. | $32.70 | 2023 | Horizant |
| Genentech USA, INC. | $31.41 | 2019-2021 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $29.87 | 2024-2025 | Caplyta |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $29.82 | 2019 | |
| Actelion Pharmaceuticals US, INC. | $27.93 | 2025 | Uptravi, Opsumit |
| Horizon Therapeutics Plc | $27.48 | 2022 | |
| Otsuka America Pharmaceutical, INC. | $23.00 | 2024 | Rexulti |
| Medtronic, INC. | $21.14 | 2024 | Intellis Adaptivestim |
| Tempus Ai, INC | $19.85 | 2024 | |
| Alvogen INC | $18.64 | 2021 | |
| Abbott Laboratories | $15.83 | 2023 | Freestyle Libre 3 |
| Dermira, INC. | $15.03 | 2020 | |
| Ethicon US, LLC | $13.88 | 2022 | |
| Idorsia Pharmaceuticals US INC | $13.46 | 2023 | Quviviq |
| Redhill Biopharma INC. | $13.14 | 2024 | Talicia |
| Hologic Sales and Service, LLC | $12.90 | 2021 | |
| Currax Pharmaceuticals LLC | $11.29 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jina Kim listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.